Peptidomimetics Therapeutics for Retinal Disease

Ocular disorders originating in the retina can result in a partial or total loss of vision, making drug delivery to the retina of vital importance. However, effectively delivering drugs to the retina remains a challenge for ophthalmologists due to various anatomical and physicochemical barriers in the eye. This review introduces diverse administration routes and the accordant pharmacokinetic profiles of ocular drugs to aid in the development of safe and efficient drug delivery systems to the retina with a focus on peptidomimetics as a growing class of retinal drugs, which have great therapeutic potential and a high degree of specificity. We also discuss the pharmacokinetic profiles of small molecule drugs due to their structural similarity to small peptidomimetics. Lastly, various formulation strategies are suggested to overcome pharmacokinetic hurdles such as solubility, retention time, enzymatic degradation, tissue targeting, and membrane permeability. This knowledge can be used to help design ocular delivery platforms for peptidomimetics, not only for the treatment of various retinal diseases, but also for the selection of potential peptidomimetic drug targets.

• Publication year

  2021

• Venue

  Biomolecules

• Publication date

  2021-02-24

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3390/biom11030339PMID 33668179PMCID 7995992
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.

  2020cited by this paper
• Molecular Surgery: Proteomics of a Rare Genetic Disease Gives Insight into Common Causes of Blindness

  2020cited by this paper
• Peptide Therapeutics 2.0

  2020cited by this paper
• Nanoconjugation and Encapsulation Strategies for Improving Drug Delivery and Therapeutic Efficacy of Poorly Water-Soluble Drugs

  2019cited by this paper
• Catechin solubilization by spontaneous hydrogen bonding with poly(ethylene glycol) for dry eye therapeutics.

  2019cited by this paper
• CD44 aptamer mediated cargo delivery to lysosomes of retinal pigment epithelial cells to prevent age-related macular degeneration

  2019cited by this paper
• Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration

  2019influential reference
• SOCS1-Derived Peptide Administered by Eye Drops Prevents Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

  2019cited by this paper
• Penetration Enhancers in Ocular Drug Delivery

  2019cited by this paper
• Ophthalmic Drug Delivery Using Iontophoresis: Recent Clinical Applications

  2019cited by this paper
• Metabolite therapy guided by liquid biopsy proteomics delays retinal neurodegeneration

  2019cited by this paper
• Effective In Vivo Topical Delivery of siRNA and Gene Silencing in Intact Corneal Epithelium Using a Modified Cell-Penetrating Peptide

  2019cited by this paper
• Corticosteroids in Moderate-To-Severe Graves’ Ophthalmopathy: Oral or Intravenous Therapy?

  2019cited by this paper
• Fmoc-diphenylalanine as a suitable building block for the preparation of hybrid materials and their potential applications.

  2019cited by this paper
• Morphology and Composition of the Inner Limiting Membrane: Species-Specific Variations and Relevance toward Drug Delivery Research

  2019cited by this paper
• The Role of Surface Active Agents in Ophthalmic Drug Delivery: A Comprehensive Review.

  2019cited by this paper
• Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties.

  2019cited by this paper
• Subretinal surgery: functional and histological consequences of entry into the subretinal space

  2019cited by this paper
• The Human Eye Proteome Project: Updates on an Emerging Proteome

  2018cited by this paper
• Ocular Drug Delivery Barriers—Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases

  2018cited by this paper
• Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline

  2018influential reference
• Nanotechnology in retinal drug delivery.

  2018cited by this paper
• A Controlled Release System for Long-Acting Intravitreal Delivery of Small Molecules

  2018cited by this paper
• Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles

  2018cited by this paper
• Intestinal absorption of small peptides: a review

  2018cited by this paper
• Cell penetrating peptides in ocular drug delivery: State of the art.

  2018cited by this paper
• Polymer–drug conjugate therapeutics: advances, insights and prospects

  2018cited by this paper
• Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

  2018cited by this paper
• Gene therapy and genome surgery in the retina

  2018cited by this paper
• Mannose and Mannose‐6‐Phosphate Receptor–Targeted Drug Delivery Systems and Their Application in Cancer Therapy

  2018cited by this paper
• Targeted Drug Delivery Via Human Epidermal Growth Factor Receptor for Sustained Release of Allyl Isothiocyanate.

  2018cited by this paper
• Improving long‐term subcutaneous drug delivery by regulating material‐bioenvironment interaction☆

  2018cited by this paper
• In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye☆

  2017cited by this paper
• Peptoids and polypeptoids: biomimetic and bioinspired materials for biomedical applications

  2017cited by this paper
• Advances in targeting the folate receptor in the treatment/imaging of cancers

  2017cited by this paper
• Implications of melanin binding in ocular drug delivery☆

  2017cited by this paper
• Discerning the composition of penetratin for safe penetration from cornea to retina.

  2017cited by this paper
• Crown Ethers: Novel Permeability Enhancers for Ocular Drug Delivery?

  2017cited by this paper
• Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution.

  2017cited by this paper
• High‐density lipoprotein mutant eye drops for the treatment of posterior eye diseases

  2017cited by this paper
• Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides.

  2017cited by this paper
• Pharmacokinetic aspects of retinal drug delivery.

  2017cited by this paper
• A novel penetratin-modified complex for noninvasive intraocular delivery of antisense oligonucleotides.

  2017cited by this paper
• Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles

  2017cited by this paper
• Therapeutic Efficacy of Nanocomplex of Poly(Ethylene Glycol) and Catechin for Dry Eye Disease in a Mouse Model.

  2017cited by this paper
• Therapeutic peptides: Historical perspectives, current development trends, and future directions.

  2017cited by this paper
• Peptidomimetic therapeutics: scientific approaches and opportunities.

  2017cited by this paper
• Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts

  2017cited by this paper
• Development of a novel stability indicating RP-HPLC method for quantification of Connexin43 mimetic peptide and determination of its degradation kinetics in biological fluids

  2017cited by this paper
• Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery

  2017cited by this paper
• Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors

  2016cited by this paper
• Cell-Penetrating Peptides as Carriers for Oral Delivery of Biopharmaceuticals.

  2016cited by this paper
• Intraocular distribution of topically applied hydrophilic and lipophilic substances in rat eyes

  2016cited by this paper
• Selenium-binding lactoferrin is taken into corneal epithelial cells by a receptor and prevents corneal damage in dry eye model animals

  2016cited by this paper
• Circumferential flow of particles in the suprachoroidal space is impeded by the posterior ciliary arteries.

  2016cited by this paper
• Design and Synthesis of New Cell Penetrating Peptides: Diffusion and Distribution Inside the Cornea.

  2016cited by this paper
• Hydrotropic Solubilization of Lipophilic Drugs for Oral Delivery: The Effects of Urea and Nicotinamide on Carbamazepine Solubility–Permeability Interplay

  2016cited by this paper
• Intraocular distribution of topically applied hydrophilic and lipophilic substances in rat eyes.

  2016cited by this paper
• Cyclic RGD peptides target human trabecular meshwork cells while ameliorating connective tissue growth factor-induced fibrosis

  2016cited by this paper
• Tat PTD-Endostatin-RGD: A novel protein with anti-angiogenesis effect in retina via eye drops.

  2016cited by this paper
• Facile Noninvasive Retinal Gene Delivery Enabled by Penetratin.

  2016cited by this paper
• Quantitative Proteomics Analysis of Vitreous Humor from Diabetic Retinopathy Patients.

  2015cited by this paper
• Vitreous substitutes: challenges and directions.

  2015cited by this paper
• Diffusion Regulation in the Vitreous Humor.

  2015cited by this paper
• Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery

  2015cited by this paper
• The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease

  2015cited by this paper
• Dexamethasone intravitreal implant in the treatment of diabetic macular edema

  2015cited by this paper
• Peptide therapeutics: current status and future directions.

  2015cited by this paper
• Insoluble drug delivery strategies: review of recent advances and business prospects

  2015cited by this paper
• Proteomic Insight into the Molecular Function of the Vitreous

  2015cited by this paper
• Structure-Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding Epitopes

  2015cited by this paper
• What is the future of PEGylated therapies?

  2015cited by this paper
• Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development.

  2015cited by this paper
• Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review

  2015cited by this paper
• Activatable cell penetrating peptide-peptide nucleic acid conjugate via reduction of azobenzene PEG chains.

  2014cited by this paper
• Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery.

  2014cited by this paper
• Proteomic analysis of human vitreous humor

  2014cited by this paper
• Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition

  2014cited by this paper
• Managing adverse effects of glaucoma medications

  2014cited by this paper
• Role of Protease-Inhibitors in Ocular Diseases

  2014cited by this paper
• Enhancement in corneal permeability of riboflavin using calcium sequestering compounds

  2014cited by this paper
• Advances in ophthalmic drug delivery.

  2014cited by this paper
• Managing adverse effects of glaucoma medications

  2014cited by this paper
• Future directions for peptide therapeutics development.

  2013cited by this paper
• Ocular drug delivery systems: An overview.

  2013cited by this paper
• Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo.

  2013cited by this paper
• Cyclodextrin-mediated enhancement of riboflavin solubility and corneal permeability.

  2013cited by this paper
• In-depth mass spectrometric mapping of the human vitreous proteome

  2013cited by this paper
• Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.

  2013cited by this paper
• Approaches for enhancing oral bioavailability of peptides and proteins.

  2013cited by this paper
• Cell‐penetrating Peptides as a Novel Transdermal Drug Delivery System

  2012cited by this paper
• Proteomic Analyses of the Vitreous Humour

  2012cited by this paper
• Chapter 4.2:Nanostructures Overcoming the Ocular Barrier: Drug Delivery Strategies

  2012cited by this paper
• Clinical pharmacology considerations in biologics development

  2012cited by this paper
• Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye.

  2012cited by this paper
• Mechanism of hydrophobic drug solubilization by small molecule hydrotropes.

  2012cited by this paper
• Selenium Compound Protects Corneal Epithelium against Oxidative Stress

  2012cited by this paper
• Ocular Sustained Release Nanoparticles Containing Stereoisomeric Dipeptide Prodrugs of Acyclovir

  2011cited by this paper
• Contribution of Saccadic Motion to Intravitreal Drug Transport: Theoretical Analysis

  2011cited by this paper
• Intraocular Pharmacokinetics of a Crystalline Lipid Prodrug, Octadecyloxyethyl-Cyclic-Cidofovir, for Cytomegalovirus Retinitis

  2011cited by this paper

• Complex Peptide Injectables: Development and Challenges

  2025cites this paper
• Eye Drop with Fas-Blocking Peptide Attenuates Age-Related Macular Degeneration

  2024cites this paper
• Synthesis and Evaluation of the Antimicrobial Activity of Cationic Amphiphiles Based on Bivalent Diethylenetriamine Derivatives

  2023cites this paper
• Peptide cargo administration: current state and applications

  2023cites this paper
• A Physiology-Based Mathematical Model to Understand Drug Delivery from Contact Lenses to the Back of the Eye

  2023cites this paper
• Thrombospondin-1 proteomimetic polymers exhibit anti-angiogenic activity in a neovascular age-related macular degeneration mouse model

  2023cites this paper
• Calpains as mechanistic drivers and therapeutic targets for ocular disease.

  2022cites this paper
• Protein and polypeptide mediated delivery to the eye.

  2022cites this paper
• An intravitreal implant injection method for sustained drug delivery into mouse eyes

  2021cites this paper
• New methods for the synthesis of phosphono-δ-lactones (microreview)

  2021cites this paper
• “Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry

  2021cites this paper